Molecular Analysis for Therapy Choice (MATCH)
for Non-Responsive or Rare Cancers

Study name: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Description: In collaboration with the National Cancer Institute (NCI), the WL Nugent Cancer Center is participating in a ground-breaking study called NCI-MATCH. This is one of the first major clinical trials to match people who have cancer with treatment based on genetic changes in their tumor rather than their type of cancer.

In this trial, people with cancer are assigned to receive treatment based on the genetic changes found in their tumors through genomic sequencing and other tests. Genomic sequencing is a laboratory method that is used to determine the genetic makeup of cancer cells. 

People whose tumors have genetic changes that match one of the treatments in the trial may receive that treatment if they meet other eligibility criteria.

The trial seeks to determine whether treating cancer based on specific genetic changes is effective, no matter the cancer type. The drugs included in the trial have either been approved by the U.S. Food and Drug Administration (FDA) for another cancer; or are still being tested in other clinical trials but have shown some effectiveness against tumors with a particular genetic change.

Who can participate?
You may be eligible for MATCH if you have an advanced solid tumor, lymphoma, or myeloma that is not improving with standard treatment; or if you have a rare cancer for which there is no standard treatment.

What to expect

  • You will meet with your oncologist to discuss what is involved in the study and the possible benefits and risks. If you and your doctor agree this clinical trial is right for you, you will be asked to sign a consent form.

  • Your oncologist will order gene testing on a tumor sample at a medical laboratory. You may not need a new tumor biopsy to take part in this trial. Instead, your oncologist may submit tumor tissue from a prior biopsy.
  • If the lab finds a genetic change in the tumor that matches with a targeted drug in the study, you will be treated with the targeted drug for as long as your tumor shrinks or remains stable.

  • You will periodically complete questionnaires about your condition, side-effects from treatment, etc.

  • Blood samples may be collected before, during, and after treatment for study analysis.


Please talk with your doctor about whether this clinical trial is right for you.